article thumbnail

Boston Pharmaceuticals Licenses Potential NASH Treatment from Novartis

BioSpace

Boston Pharmaceuticals licensed the drug candidate BOS-580, an injectable, genetically engineered variant of human FGF21.

Licensing 111
article thumbnail

ERS Genomics and Japan SLC Sign CRISPR/Cas9 License Agreement

BioTech 365

ERS Genomics and Japan SLC Sign CRISPR/Cas9 License Agreement ERS Genomics and Japan SLC Sign CRISPR/Cas9 License Agreement Nobel prize winning CRISPR technology to be applied in development of genetically engineered animal models DUBLIN & SHIZUOKA, Japan–(BUSINESS WIRE)–ERS Genomics Limited, … Continue reading →

Genome 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

ERS Genomics and Setsuro Tech Sign CRISPR/Cas9 License Agreement

BioTech 365

ERS Genomics and Setsuro Tech Sign CRISPR/Cas9 License Agreement ERS Genomics and Setsuro Tech Sign CRISPR/Cas9 License Agreement Nobel prize winning CRISPR technology to be applied in development of genetically engineered cell and animal models DUBLIN & TOKUSHIMA, Japan–(BUSINESS WIRE)–ERS … Continue reading →

Genome 40
article thumbnail

Crescita Announces Licensing Agreement for Pliaglis; in China

The Pharma Data

Ltd (“Juyou”), a biotechnology company that develops and sells medical and cosmetic skincare products, for the commercialization and development of Pliaglis ® in mainland China (the “License Agreement”). million and US$1.8

article thumbnail

NICE recommends first CAR-T cell therapy on NHS in England

pharmaphorum

CAR-T cell therapy is an individualised treatment for patients, currently licensed for people living with some types of blood cancer. More specifically, CAR-T cell therapy engineers a patient’s own immune cells (T-cells) to detect, target, and destroy cancer cells.

article thumbnail

CRISPR Therapeutics begins natural killer cell cancer tie-up with Nkarta

pharmaphorum

CRISPR’s deal with Nkarta aims to create genetically engineered NK cells, which are harvested and used to create a bank of “off the shelf” cells that can administered to patients like a drug. Nkarta also gets a license to CRISPR gene editing to an unlimited number of its own NK cell therapy products.

article thumbnail

Novartis’ Ilaris fails in late-stage COVID-19 trial

pharmaphorum

Novartis noted that the results from this trial do not affect Ilaris’ licensed indications or other trials and the safety profile was comparable to placebo plus standard of care. Novartis is also working with Molecular Partners to develop therapies based on genetically engineered proteins known as DARPins.

Trials 40